Kono Masakazu, Hirota Kousuke, Yokoe Ayako, Koumura Chie, Sakai Toshihiko, Tojima Hirokazu
Department of Pulmonary Medicine, Tokyo Rosai Hospital, Japan.
Intern Med. 2014;53(16):1825-7. doi: 10.2169/internalmedicine.53.2307. Epub 2014 Aug 15.
We herein describe the case of a 74-year-old man who experienced pulmonary consolidation and chest pain following administration of dabigatran, a novel oral anticoagulant. The consolidation settled spontaneously in another lung area, a condition sometimes referred to as "wandering pneumonia." Although we did not find specific pathological evidence of interstitial lung disease on transbronchial lung biopsy, a lung opacity spontaneously disappeared following discontinuance of dabigatran, and there was no recurrence. There are no other reports of dabigatran-induced lung injury, except alveolar hemorrhage and eosinophilic pneumonia. We should consider that any novel drug could cause various types of pulmonary injuries.
我们在此描述了一名74岁男性的病例,该患者在服用新型口服抗凝剂达比加群后出现了肺部实变和胸痛。实变在另一个肺区域自行消散,这种情况有时被称为“游走性肺炎”。尽管我们在经支气管肺活检中未发现间质性肺疾病的具体病理证据,但在停用达比加群后肺部阴影自行消失,且未复发。除肺泡出血和嗜酸性粒细胞性肺炎外,尚无其他关于达比加群所致肺损伤的报道。我们应考虑到任何新药都可能导致各种类型的肺部损伤。